The estimated Net Worth of Steven J O'day is at least $564 Thousand dollars as of 4 January 2022. Dr day owns over 100,000 units of Agenus Inc stock worth over $564,000 and over the last 3 years he sold AGEN stock worth over $0.
Dr has made over 1 trades of the Agenus Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of AGEN stock worth $564,000 on 4 January 2022.
The largest trade he's ever made was exercising 100,000 units of Agenus Inc stock on 4 January 2022 worth over $564,000. On average, Dr trades about 20,000 units every 0 days since 2022. As of 4 January 2022 he still owns at least 100,000 units of Agenus Inc stock.
You can see the complete history of Dr day stock trades at the bottom of the page.
Dr. Steven J. O'Day M.D., Ph.D. is the Chief Medical Officer at Agenus Inc.
Steven's mailing address filed with the SEC is C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON, MA, 02421.
Over the last 23 years, insiders at Agenus Inc have traded over $24,466,328 worth of Agenus Inc stock and bought 13,248,226 units worth $63,837,873 . The most active insiders traders include Associates Gp Llcqvt Fund V..., Noubar Afeyan, and Corp Incyte. On average, Agenus Inc executives and independent directors trade stock every 99 days with the average trade being worth of $2,230,885. The most recent stock trade was executed by Garo H Armen on 15 February 2024, trading 500,000 units of AGEN stock currently worth $325,000.
agenus is an immunology company discovering and developing novel checkpoint modulators, vaccines and adjuvants to treat cancer and other diseases. we are a dedicated group of scientists, researchers, biotechnologists, physicians, and businesspeople working together toward one goal: to discover and develop therapies that can unleash the innate power of the body’s immune system to treat and potentially cure hard-to-treat cancers and other diseases. our product candidates are designed to work by educating and activating the body’s immune system for a precise and potent attack on cancer. our strategy is to help unlock the potential of one of the most exciting breakthrough areas in cancer treatment in decades, and to develop single agent and combination immune-oncology therapies that can help save lives. our approaches are driven by three platform technologies, including: • our antibody platforms, including our proprietary retrocyte display™ and secant® technologies, and our antibody
Agenus Inc executives and other stock owners filed with the SEC include: